News (200)

Moderna : 2024 Proxy Statement PU
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences AQ
Moderna, Inc. prepares for the post-Covid era Our Logo
Moderna Chief Executive Officer Stephane Bancel Elected to National Academy of Engineering AQ
Transcript : Alexandria Real Estate Equities, Inc., Q4 2023 Earnings Call, Jan 30, 2024
Transcript : Alexandria Real Estate Equities, Inc. - Analyst/Investor Day
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics PR
Moderna Chairman Afeyan on Industry Outlook, Strategy, AI MT
Moderna, Inc. : melts like snow in the sun Our Logo
Flagship Pioneering Launches Pioneering Intelligence PR
Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel Medicines PR
Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise RE
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR
Omega Therapeutics, Inc. Announces Board Changes CI
Omega Therapeutics Announces Updates to its Board of Directors GL
Omega Therapeutics, Inc. Appoints Chris Schade as Chairman of the Board CI
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines AQ
ALLTRNA ANNOUNCES SERIES B RAISE OF $109 MILLION TO ADVANCE TRNA MEDICINES FOR STOP CODON DISEASE AQ
Flagship Pioneering Announces Appointment of Rupert Vessey as Chief Scientist AQ
Omega Therapeutics Appoints Chris Schade to its Board of Directors GL
Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs PR
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry PR
Axcella Health : 10K HTML Q4 22 PU
RUBIUS THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K) AQ
Transcript : Omega Therapeutics, Inc. Presents at H.C. Wainwright 24th Annual Global Investment Conference, Sep-12-2022 10:00 AM
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors PR
Evelo Biosciences Announces Succession Plan GL
OMEGA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Rubius Therapeutics : Appoints Noubar Afeyan as Chairman of its Board of Directors - Form 8-K PU
RUBIUS THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) AQ
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors GL
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors CI
MODERNA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Moderna to open vaccine factory in Canada, its first abroad AQ
Transcript : Moderna, Inc. - Shareholder/Analyst Call
Abbvie Vice Chairman Severino Departs for Flagship Pioneering DJ
Moderna to Set Up Sh60bn Covid Vaccine Plant in Kenya, the First in Africa AQ
Moderna : Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa PU
Moderna : Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29 Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023 Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax PU
Moderna : Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates PU
General Electric : GE Digital’s Colin Parris Elected as a Member of the National Academy of Engineers (NAE) PU
Flagship Pioneering Announces Appointment of Tom DiLenge as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy PR
Flagship Pioneering Launches Harbinger Health to Detect Early Cancer with a Simple, Bio-AI Based Blood Test PR
Omicron variant found in nearly one-third of U.S. states RE
Omicron variant found in nearly one-third of U.S. states RE
1234NextSee all

Insiders

Picture Noubar Afeyan
Noubar Afeyan

Noubar B. Afeyan, Ph.D. has served as a member of our board of directors since 2013. Previously, Dr. Afeyan served as our President from April 2013 to May 2014 and as the Chairman of our board of directors from April 2013 to December 2014 and from July 2016 to January 2017. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since August 2010, Dr. Afeyan has served on the board of directors of Moderna, Inc. He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Seres Therapeutics, Inc., Evelo Biosciences, Inc., Kaleido Biosciences, Inc. and BG Medicine, Inc. He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School. We believe that Dr. Afeyan’s significant experience co-founding, leading and investing in numerous biotechnology companies make him qualified to serve on our board of directors.


Picture Noubar Ghazarossian
Noubar Ghazarossian

Noubar Ghazarossian is Senior Director of Reliance Globalcom Services, Inc. He joined Yipes in December 2002.
Mr. Ghazarossian worked at Pacific Bell, AT&T, Bank of America, Price Waterhouse, MCA Universal, Sony Pictures Entertainment, and Louis Vuitton Moet Hennessey.
He has over 25 years in senior management experience focusing on operations, business-to-business commerce, business process management, and global network management.
Mr. Ghazarossian received an MBA in Telecommunications Management and a BS degree in Information Sciences from Golden Gate University.








Picture Noubar Takessian
Noubar Takessian

Noubar Takessian currently works as a Director at Professional Engineers Ontario.


Picture Raffi Afeyan
Raffi Afeyan

Raffi Afeyan is the founder.
He founded Ampersand Biomedicines, Inc. in 2000, where he currently holds the title of Chief Innovation Officer.
He is also currently working as a Senior Principal at Flagship Pioneering since 2021.
In his former positions, he served as Vice President at Cellarity Inc. and Generate Biomedicines, Inc. Mr. Afeyan has a graduate degree from Boston University and an undergraduate degree from McGill University.

No results for this search